Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

著者: Mark G. Kris, D. Ross Camidge, Giuseppe Giaccone, Toyoaki Hida, Bob T. Li, Joseph O’Connell, Ian W. Taylor, H. Zhang, Maria E. Arcila, Zelanna Goldberg, Pasi A. Jänne - Annals of Oncology 2015 被引用: 332